Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
205.44
-3.14 (-1.51%)
At close: Dec 5, 2025, 4:00 PM EST
206.00
+0.56 (0.27%)
After-hours: Dec 5, 2025, 5:55 PM EST
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$745,912
Profits / Employee
-$268,740
Market Cap
12.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ASND News
- 1 day ago - Ascendis: Q3 Results Validate The TransCon Platform - Seeking Alpha
- 7 days ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 10 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 10 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire
- 18 days ago - Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics - GlobeNewsWire
- 23 days ago - Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Ascendis Pharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga